SCHEMBL3399751

SCHEMBL3399751

CCOC(=O)c1sc(Cl)nc1C(=O)NNC(C)=O

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.48
ALDH1A1 P00352 8/20 0.47
HPGD P15428 6/20 0.47
CYP1A2 P05177 2/20 0.47
TSHR P16473 2/20 0.44
ALOX15 P16050 1/20 0.41
NPC1 O15118 2/20 0.40
TP53 P04637 4/20 0.40
MAPT P10636 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
TRPM8 Q7Z2W7 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
KDM4E B2RXH2 2/20 0.39
RAB9A P51151 2/20 0.39
HSD17B10 Q99714 1/20 0.39
HSP90AA1 P07900 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3403523 0.84 ALDH1A1 (0.45) GAAALDH1A1HPGDCYP1A2TSHR
SCHEMBL1554058 0.83 ALDH1A1 (0.49) GAAALDH1A1HPGDCYP1A2TSHR
SCHEMBL1505552 0.82 ALDH1A1 (0.66) GAAALDH1A1HPGDCYP1A2TSHR
SCHEMBL1553145 0.82 SMN1; SMN2 (0.48) GAAALDH1A1HPGDCYP1A2TSHR
SCHEMBL1553485 0.81 ALDH1A1 (0.47) GAAALDH1A1HPGDCYP1A2TSHR
SCHEMBL1553279 0.81 ALDH1A1 (0.47) GAAALDH1A1HPGDCYP1A2TSHR
SCHEMBL1553063 0.80 ALDH1A1 (0.54) GAAALDH1A1HPGDCYP1A2TSHR
SCHEMBL1553046 0.80 ALDH1A1 (0.54) GAAALDH1A1HPGDCYP1A2TSHR
SCHEMBL2826239 0.80 ALDH1A1 (0.54) GAAALDH1A1HPGDCYP1A2TSHR
SCHEMBL1553587 0.79 ALDH1A1 (0.45) GAAALDH1A1HPGDCYP1A2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2158199-B1 PIPERIDINE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2010-11-17 EP disclosed
EP-2158199-B1 PIPERIDINE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2010-11-17 EP disclosed
EP-2158199-A1 PIPERIDINE COMPOUNDS AND USES THEREOF AstraZeneca AB (SE) 2010-03-03 EP disclosed
WO-2008152418-A1 PIPERIDINE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2008-12-18 WO disclosed
WO-2008152418-A1 PIPERIDINE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2008-12-18 WO disclosed
US-20080312255-A1 PIPERDINE COMPOUNDS AND USES THEREOF-911 ASTRAZENECA AB (SE) 2008-12-18 US disclosed
US-20080312255-A1 PIPERDINE COMPOUNDS AND USES THEREOF-911 ASTRAZENECA AB (SE) 2008-12-18 US disclosed
US-20080312255-A1 PIPERDINE COMPOUNDS AND USES THEREOF-911 ASTRAZENECA AB (SE) 2008-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312255-A1 PIPERDINE COMPOUNDS AND USES THEREOF-911 NISCH, PIR, QDPR GAA 494/4885ALDH1A1 243/4885HPGD 394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.